Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 5/20 | 0.36 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13916066 | 0.89 | GART (0.45) | GARTFOLR1DHFRALDH1A1HPGD | |
| SCHEMBL6900553 | 0.88 | GART (0.47) | GARTFOLR1DHFR | |
| SCHEMBL6902020 | 0.77 | SMN1; SMN2 (0.39) | GARTDHFRSMN1; SMN2NPC1HTT | |
| SCHEMBL9836685 | 0.75 | GART (0.42) | GARTDHFRALDH1A1HPGD | |
| SCHEMBL6899022 | 0.75 | GART (0.61) | GARTFOLR1 | |
| SCHEMBL6900347 | 0.75 | GART (0.61) | GARTFOLR1 | |
| SCHEMBL6899009 | 0.75 | GART (0.61) | GARTFOLR1 | |
| SCHEMBL9837146 | 0.75 | GART (0.41) | GARTDHFRALDH1A1HPGD | |
| SCHEMBL7834566 | 0.74 | GART (0.55) | GARTFOLR1 | |
| SCHEMBL10512971 | 0.74 | GART (0.58) | GARTDHFRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-0773943-B1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMA (US) | 2001-09-26 | — | — | EP | disclosed |
| US-5646141-A | THIENYLALKYLATED DERIVATIVES OF PYRIDO(2,3-D)-PYRIMIDINE, PYRIMIDO(5,4-6)-(1,4)THIAZINE OR PYRIMIDO(5,4-6)-(1,4)SELENAZINE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5608082-A | GARFT = THE ENZYME GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | GART 4/4885FOLR1 343/4885DHFR 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.